Biomarkers for Taxane Sensitivity and Hormonal Resistance in Patients with Castration-Resistant Prostate Cancer.

摘要

This is an annual report for a one year Hypothesis Development award initially accepted for funding 1/4/2013. Because of sequestration and delays in approvals between UW and DOD, the award was initiated 2/1/2014. The objective of this project was to utilize the presence of splice variant androgen receptor (AR) in circulating tumor cells (CTC) or disseminated tumor cells (DTC) to predict sensitivity to chemotherapy (docetaxel). Progress: Aims 1 and 2 are nearly complete. Aim 1, which was to confirm that prostate cancer cells spiked with AR splice variant expressing cells and transcriptome could be detected has been completed with the Adnagen CTC assay after initial failure of the Rarecyte assay to reliably isolated CTC. Aim 2 was to detect CTC and DTC from men with advanced prostate cancer. We have collected matched CTC, DTC and metastasis biopsies on 21 patients with metastatic prostate cancer. Please see the detailed report for information regarding the presence of new types of AR splice variants detected in metastasis biopsies. The final analysis of the types of splice variants in the biopsies and correlation with presence of the same splice variants in CTC and DTC is pending and is anticipated within six months.